Mylan Denied Invalidity In Cancer Drug IP Battle

Law360, New York (May 2, 2012, 5:42 PM EDT) -- A Delaware federal judge Tuesday found in favor of Genentech Inc., Pfizer Inc. and Astellas Pharma Inc. unit OSI Pharmaceuticals Inc. in their patent infringement suit against Mylan Pharmaceuticals Inc. over its generic version of the lung cancer drug Tarceva.

U.S. District Judge Sue L. Robinson struck down Mylan's arguments that two OSI patents — one of which is co-owned by Pfizer, while the other is exclusively licensed to Genentech — on the drug were invalid because they were obvious based on prior patented formulations....
To view the full article, register now.